GIGABYTE
GIGABYTE, a leading supplier of computer hardware and pioneer in the tech industry, presents “Power of Computing” at CES 2023 to demonstrate exceptional computing prowess that drives innovative technologies forward. An extensive range of enterprise and personal computer solutions are brought to the show to resonate with the theme.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005713/en/
GIGABYTE at CES 2023: Power of Computing to Reshape the World (Photo: Business Wire)
- Data Center Servers: Computing breakthroughs that propel next-gen technologies and AI applications.
- Advanced Cooling Solutions: Computing performance and environmental sustainability in harmony.
- Mobile Computing Platforms: Zonal computing to enable a safer and greener transportation.
- PCs and Laptops: Next-gen performance delivered for digital natives.
Data Center is an integral part of making technological breakthroughs. GIGABYTE has always been trusted as a pioneer in developing new server products for developers, and worked on software integrations to provide product solutions that are in line with the future of the digital age. GIGABYTE brought to CES its next-gen server hardware and computing technology that unleashes greater performance, improved energy efficiency, and is ready for high-density compute with the latest CPUs and GPUs to accelerate workloads of any scale. Also showcased is an enterprise-grade workstation that coupled with MyelinTek’s ready-to-go MLOps AI development environment. The MLOps’s easy-to-use interface enables engineers to quickly train AI models suited for their innovations, and the workstation’s outstanding performance allows a painless implementation.
Computing demands are facing a thermal dilemma in which performance gain is at environment’s sacrifice. GIGABYTE’s Air, Liquid, and Immersion Cooling Solutions are specially designed to increase heat dissipation efficiency, empowering servers to deliver exceptional high performance while lowering carbon emissions, paving the way for a sustainable future without sacrificing economic growth. At its CES booth GIGABYTE also debuts TO15-Z40, which is an OCP server compatible with all major immersion tanks, to show the most future-proof computing to industry leaders who wish to create a balance in tech advancements and environmental sustainability.
Vehicle tech is thriving as it leverages the power of computing to helm artificial intelligence and communications, therefore paving way for safer driving and smarter traffic. With extensive experience in developing ADCU (Autonomous Driving Control Unit) and ADAS DCU (Domain Control Unit), GIGABYTE provides the automotive industry with high-performance Zonal Integrated DCUs and decision-making control hosts, which are built with a centralized architecture and can be integrated into various requirements and design concepts, lowering vehicle production costs.
GIGABYTE launched its newest iteration of AERO creator laptops and AORUS gaming laptops just in time before CES begins. Both laptops series are built with 13th gen Intel® Core™ processors and NVIDIA RTX™ 40 series graphics cards, and in addition, are designed with the latest technologies, to present tech fanatics with computing performance that exceeds their expectations. The newly crowned CES 2023 Innovation Award winner, Stealth 500 PC DIY Kit, and a whopping 48” gaming monitor are also showcased for users to feast their eyes on.
Visit GIGABYTE ‘Power of Computing’ event page
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005713/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom